UNSPSC 51371900: Controlled substance analgesic methadones

Controlled substance analgesic drugs made from a synthetic ketone opioid 6-(dimethylamino)-4,4-diphenylheptan-3-one.

UNSPSC 51371900 Controlled substance analgesic methadones, a Class code, encompasses pharmaceutical procurement by state and local health agencies, though recent solicitations tagged to this code show a broader scope including naloxone, generic multi-source pharmaceuticals, and over-the-counter products distributed through state and local health systems and cooperative purchasing networks. State and local health departments, county community health programs, and multistate cooperative purchasing alliances—such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP)—use this code to acquire pharmaceutical products for public health delivery. Vendors must typically comply with Drug Supply Chain Security Act (DSCSA) certification, current Good Manufacturing Practices (cGMP), FDA requirements, and federal workplace and environmental compliance mandates. Contracts generally require fixed-fee or net-pricing models with performance penalties for non-compliance, substantial insurance coverage (including commercial general liability and professional liability), and demonstrated capacity to distribute through authorized wholesalers or directly to county health facilities.

Recent activity spans Florida, Texas, and Minnesota, with the most active solicitation being MMCAP's Request for Proposal S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, requiring vendors to work through three authorized wholesalers and submit detailed NDC, SKU, and pricing data. Seminole County, Florida issued Invitation for Bid IFB60459723LAS (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas Health and Human Services Commission issued Request for Information HHS0017013 (response deadline April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking vendors experienced in direct contracting with self-insured health plans and government agencies using negotiated net pricing models. MMCAP contracts run two years for new vendors with optional extensions, while county-level agreements typically include one-year renewal options; both structure awards on price competitiveness, compliance capability, and therapeutic or patient-safety considerations.